Condition (MeSH)
Erythromelalgia
ClinicalTrials.gov lists 8 trials for Erythromelalgia or a narrower condition beneath it. Xenon Pharmaceuticals Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with Erythromelalgia itself; the rest are tagged with a narrower condition beneath it.
When did Erythromelalgia trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2014 | 1 |
| 2012 | 1 |
| 2011 | 1 |
| 2010 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Erythromelalgia trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 2 |
| Phase 2 | 1 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 1 |
How many Erythromelalgia trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 5 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Erythromelalgia trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Xenon Pharmaceuticals Inc. | 2 |
| AlgoTherapeutix | 1 |
| Biohaven Therapeutics Ltd. | 1 |
| VA Connecticut Healthcare System | 1 |
Which serious adverse events do Erythromelalgia trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hospitalization due to worsening erythromelalgia pain | 1 | 1 |
Which publications cover Erythromelalgia? (16)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The role of Nav1.7 in human nociceptors: insights from human induced pluripotent stem cell-derived sensory neurons of erythromelalgia patients. | Pain | 2019 | Yes |
| Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia. | Science translational medicine | 2016 | Yes |
| Small-fibre neuropathy related to bulbar and spinal-onset in patients with ALS. | Journal of neurology | 2015 | Yes |
| Corneal confocal microscopy shows an improvement in small-fiber neuropathy in subjects with type 1 diabetes on continuous subcutaneous insulin infusion compared with multiple daily injection. | Diabetes care | 2015 | Yes |
| Small fiber neuropathy in women with fibromyalgia. An in vivo assessment using corneal confocal bio-microscopy. | Seminars in arthritis and rheumatism | 2015 | Yes |
Showing 5 of 16 publications.
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Primary erythromelalgia | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Primary erythromelalgia | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
| Primary erythromelalgia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Primary erythromelalgia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Primary erythromelalgia | 90026 | Exact | Orphadata Science knowledge files, Product 1 |
| Primary erythromelalgia | 90026 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.